 |
 |
|
|
Articles 
Robert J. Green, Joshua P. Metlay, Kathleen Propert, Paul J. Catalano, John S. Macdonald, Robert J. Mayer, and Daniel G. Haller The incidence of second primary colorectal cancer after treatment for localized colon cancer remains high despite intensive surveillance strategies.
Morten Dahl, Anne Tybjærg-Hansen, Peter Lange, Jørgen Vestbo, and Børge G. Nordestgaard A deteriorating effect of severe
Dino Vaira, Nimish Vakil, Marcello Menegatti, Ben van't Hoff, Chiara Ricci, Luigi Gatta, Giovanni Gasbarrini, Mario Quina, Jose M. Pajares Garcia, Arie van der Ende, Rene van der Hulst, Marcello Anti, Cristina Duarte, Javier P. Gisbert, Mario Miglioli, and Guido Tytgat A positive result on the stool antigen test 7 days after completion of therapy identifies patients in whom eradication of Helicobacter pylori was unsuccessful.
Brief Communications
Yngve Falck-Ytter, Hemangi Kale, Kevin D. Mullen, Steedman A. Sarbah, Lucian Sorescu, and Arthur J. McCullough Most patients with hepatitis C virus infection are not candidates for interferon-based therapies; alternative interventions should be sought for these patients.
Reviews
J. John Mann Suicide is generally a complication of a psychiatric disorder, but it requires additional risk factors because most psychiatric patients never attempt suicide. This review includes a hypothesized stress–diathesis model, which has implications for detection of high-risk patients and treatment interventions, and discusses promising treatment approaches.
Medicine and Public Issues
Peter D. Weinberg, Jennie Hounshell, Laurence A. Sherman, John Godwin, Shirin Ali, Cecilia Tomori, and Charles L. Bennett This paper summarizes the current status of concerns about the safety of the blood supply in developed countries, where viral transmission from contaminated blood or blood products is extremely rare, and in developing countries, where up to 10% of HIV infections result from transfusion of blood or blood products.
NIH Conferences
Deborah P. Merke, Stefan R. Bornstein, Nilo A. Avila, and George P. Chrousos In the past 50 years, since the discovery of cortisone therapy as an effective treatment for congenital adrenal hyperplasia, many advances have been made in the study and management of 21-hydroxylase deficiency. The discovery of the 21-hydroxylase gene was followed by the discovery of the 21-hydroxylase–deficient mouse, which has provided a useful model for testing new treatments. As our knowledge of this disease expands, new therapies are being developed and tested in both humans and animals.
Editorials
Paul J. Limburg and David A. Ahlquist Although the study by Green and colleagues in this issue chronicles a disturbingly high rate of second primary colorectal cancer in patients undergoing surveillance in an adjuvant chemotherapy trial, the junctures at which corrective measures are most needed cannot be precisely determined. For now, adherence to the existing consensus guidelines for postoperative surveillance seems warranted until convincing evidence supports alternative strategies.
Letters Physicians and Capital Punishment
Pharmacist Scope of Practice
Influenza: Prospects for Control
Quinine-Induced Blindness Reversed by an Increase in
Ellen F. Manzullo and Roger W. Anderson
Howard Schubiner and Susan Eggly
Robert K. Schneider and James L. Levenson This Update is the first Update in Psychiatry presented at an Annual Session of the American College of Physicians–American Society of Internal Medicine. The authors cover the following topics: mood disorders, anxiety disorders, geropsychiatry, and new therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue
1-antitrypsin deficiency (ZZ genotype) on lung function is well known, whereas the role of intermediate deficiency (MZ genotype) remains uncertain. This study found that MZ heterozygotes had a slightly greater rate of decrease in FEV1 and were modestly over-represented among persons with airway obstruction and chronic obstructive pulmonary disease (COPD). In the population at large, MZ heterozygosity may account for a fraction of COPD cases—on the order of 2%, similar to the percentage of persons with COPD who have the severe but rare ZZ genotype. 